Fig. 5: MSI2 and β-catenin correlate and interact in primary AML patient samples. | Oncogene

Fig. 5: MSI2 and β-catenin correlate and interact in primary AML patient samples.

From: β-Catenin interacts with canonical RBPs including MSI2 to associate with a Wnt signalling mRNA network in myeloid leukaemia cells

Fig. 5

A Immunoblot of 18 myeloid leukaemia cell lines showing the relative level of β-catenin and MSI2 protein, with GAPDH used to assess protein loading. B Summary scatter plot showing the correlation (Spearman Rank R = 0.6, P < 0.03) between relative β-catenin and MSI2 protein expression across 18 myeloid cell lines as deduced from densitometry (normalised to GAPDH expression present within each cell line, AU = arbitrary units). C Immunoblot screen of 20 primary AML patient samples showing the relative level of β-catenin and MSI2 protein (light and dark exposures). * Denotes samples co-overexpressing both β-catenin and MSI2 relative to levels in CB MNC and CB CD34+ enriched fraction (pooled from five independent CB samples). X = Void sample containing no protein as deduced from negative GAPDH detection. D Summary scatter plot showing the correlation (Spearman Rank R = 0.79, P < 0.0001) between relative β-catenin and MSI2 protein expression across 20 primary AML patient samples as deduced from densitometry (normalised to GAPDH expression present in each sample, AU = arbitrary units). E Immunoblot showing the level of β-catenin and GAPDH protein present in an MSI2 Co-IP performed from primary AML patient sample #10 of sample screen.

Back to article page